111 related articles for article (PubMed ID: 11360189)
21. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.
Ruteshouser EC; Hendrickson BW; Colella S; Krahe R; Pinto L; Huff V
Genes Chromosomes Cancer; 2005 Jun; 43(2):172-80. PubMed ID: 15761866
[TBL] [Abstract][Full Text] [Related]
22. Case of interstitial 12q deletion in association with Wilms tumor.
Rapley EA; Hargrave D; Persinguhe N; Barfoot R; Moore I; Radford M; Stratton MR; Rahman N; Pritchard-Jones K
Am J Med Genet; 2001 Dec; 104(3):246-9. PubMed ID: 11754052
[TBL] [Abstract][Full Text] [Related]
23. Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation.
Popović Hadzija M; Radosevic S; Kovacević D; Lukac J; Hadzija M; Spaventi R; Pavelić K; Kapitanović S
Mutat Res; 2004 Apr; 548(1-2):61-73. PubMed ID: 15063137
[TBL] [Abstract][Full Text] [Related]
24. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation.
Kittiniyom K; Mastronardi M; Roemer M; Wells WA; Greenberg ER; Titus-Ernstoff L; Newsham IF
Genes Chromosomes Cancer; 2004 Jul; 40(3):190-203. PubMed ID: 15138999
[TBL] [Abstract][Full Text] [Related]
25. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
26. Cadherins in Wilms' tumor: E-cadherin expression despite absence of WT1.
Baudry D; Cabanis MO; Patte C; Zucker JM; Pein F; Fournet JC; Sarnacki S; Junien C; Jeanpierre C
Anticancer Res; 2003; 23(1A):475-8. PubMed ID: 12680252
[TBL] [Abstract][Full Text] [Related]
27. Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14.
Perotti D; De Vecchi G; Testi MA; Lualdi E; Modena P; Mondini P; Ravagnani F; Collini P; Di Renzo F; Spreafico F; Terenziani M; Sozzi G; Fossati-Bellani F; Radice P
Hum Mutat; 2004 Nov; 24(5):400-7. PubMed ID: 15459955
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of a 7p15-21 homozygous deletion in a Wilms tumor.
Sossey-Alaoui K; Vieira L; David D; Boavida MG; Cowell JK
Genes Chromosomes Cancer; 2003 Jan; 36(1):1-6. PubMed ID: 12461744
[TBL] [Abstract][Full Text] [Related]
29. Identification of a minimal region of loss on the short arm of chromosome 1 in Wilms tumor.
Tamimi Y; Ziebart K; Desaulniers N; Dietrich K; Grundy P
Genes Chromosomes Cancer; 2007 Apr; 46(4):327-35. PubMed ID: 17243164
[TBL] [Abstract][Full Text] [Related]
30. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
31. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
33. Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor.
Kusafuka T; Miao J; Kuroda S; Udatsu Y; Yoneda A
Int J Mol Med; 2002 Oct; 10(4):395-9. PubMed ID: 12239584
[TBL] [Abstract][Full Text] [Related]
34. Regulatory subunit type I-alpha of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer.
Sandrini F; Matyakhina L; Sarlis NJ; Kirschner LS; Farmakidis C; Gimm O; Stratakis CA
Genes Chromosomes Cancer; 2002 Oct; 35(2):182-92. PubMed ID: 12203783
[TBL] [Abstract][Full Text] [Related]
35. Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors.
Vieyra D; Senger DL; Toyama T; Muzik H; Brasher PM; Johnston RN; Riabowol K; Forsyth PA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5952-61. PubMed ID: 14676120
[TBL] [Abstract][Full Text] [Related]
36. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study.
Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K
J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional regulation by the Wilms' tumour suppressor protein WT1.
Wagner KJ; Roberts SG
Biochem Soc Trans; 2004 Dec; 32(Pt 6):932-5. PubMed ID: 15506928
[TBL] [Abstract][Full Text] [Related]
38. Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation.
Lugtenberg RT; Cransberg K; Loos WJ; Wagner A; Alders M; van den Heuvel-Eibrink MM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1039-44. PubMed ID: 18273617
[TBL] [Abstract][Full Text] [Related]
39. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers.
Gunduz M; Ouchida M; Fukushima K; Ito S; Jitsumori Y; Nakashima T; Nagai N; Nishizaki K; Shimizu K
Oncogene; 2002 Jun; 21(28):4462-70. PubMed ID: 12080476
[TBL] [Abstract][Full Text] [Related]
40. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
